With the emergence of a promising approach to treat Alzheimer disease (AD) targeting the beta-amyloid (A beta) pathway, it is necessary to establish new diagnostic biomarkers that enable the antemortem diagnosis of AD. Although plasma A beta has been suggested as a non-invasive biomarker, its significance has been inconclusive. Thus, it is important to improve the diagnostic potential of plasma A beta. One of the potential approaches is to modify plasma A beta level using various modulators. In this study, we evaluated the influence of glucometabolic status on plasma A beta level in two lines of AD transgenic mouse. The present study demonstrated that plasma A beta level rapidly increased after glucose loading. More importantly, the magnitude of the increase in plasma A beta was significantly larger in AD transgenic mice than in wildtype littermates. These findings might Provide a novel diagnostic tool for AD using the elevation of plasma A beta level after glucose loading. (C) 2009 Elsevier Inc. All rights reserved.